The global PD-1 and PDL-1 Inhibitors market growth is projected to reach US$ 47240 million in 2025 to US$ 71940 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.

Global PD-1 and PDL-1 Inhibitors Market Trends And Outlook 2025-31

The global PD-1 and PDL-1 Inhibitors market size is predicted to grow from US$ 47240 million in 2025 to US$ 71940 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031. PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry. Infinity Market Research newest research report, the ?PD-1 and PDL-1 Inhibitors Industry Forecast? looks at past sales and reviews total world PD-1 and PDL-1 Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected PD-1 and PDL-1 Inhibitors sales for 2025 through 2031. With PD-1 and PDL-1 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 and PDL-1 Inhibitors industry. This Insight Report provides a comprehensive analysis of the global PD-1 and PDL-1 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 and PDL-1 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global PD-1 and PDL-1 Inhibitors market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 and PDL-1 Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 and PDL-1 Inhibitors. This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 and PDL-1 Inhibitors market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Pembrolizumab &nbsp;&nbsp;&nbsp; Nivolumab &nbsp;&nbsp;&nbsp; Atezolizumab &nbsp;&nbsp;&nbsp; Durvalumab &nbsp;&nbsp;&nbsp; Avelumab Segmentation by Application: &nbsp;&nbsp;&nbsp; Stomach Cancer &nbsp;&nbsp;&nbsp; Liver Cancer &nbsp;&nbsp;&nbsp; Kidney Ccancer &nbsp;&nbsp;&nbsp; Bladder Cancer &nbsp;&nbsp;&nbsp; Cervical Cancer &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; GlaxoSmithKline plc &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company &nbsp;&nbsp;&nbsp; Arcus Biosciences, Inc. &nbsp;&nbsp;&nbsp; Agenus Inc &nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd &nbsp;&nbsp;&nbsp; Astra Zeneca PLC &nbsp;&nbsp;&nbsp; Beigene Ltd &nbsp;&nbsp;&nbsp; Incyte Corporation &nbsp;&nbsp;&nbsp; Biocad &nbsp;&nbsp;&nbsp; CStone Pharmaceuticals &nbsp;&nbsp;&nbsp; Ono Pharmaceutical &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Shanghai Junshi Bioscience Co. Ltd &nbsp;&nbsp;&nbsp; Shanghai Henlius Biotech, Inc. &nbsp;&nbsp;&nbsp; Jiangsu HengRui Medicine Co., Ltd. Key Questions Addressed in this Report What is the 10-year outlook for the global PD-1 and PDL-1 Inhibitors market? What factors are driving PD-1 and PDL-1 Inhibitors market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do PD-1 and PDL-1 Inhibitors market opportunities vary by end market size? How does PD-1 and PDL-1 Inhibitors break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for PD-1 and PDL-1 Inhibitors by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for PD-1 and PDL-1 Inhibitors by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 PD-1 and PDL-1 Inhibitors Segment by Type &nbsp;2.2.1 Pembrolizumab &nbsp;2.2.2 Nivolumab &nbsp;2.2.3 Atezolizumab &nbsp;2.2.4 Durvalumab &nbsp;2.2.5 Avelumab &nbsp;2.3 PD-1 and PDL-1 Inhibitors Sales by Type &nbsp;2.3.1 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global PD-1 and PDL-1 Inhibitors Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Type (2020-2025) &nbsp;2.4 PD-1 and PDL-1 Inhibitors Segment by Application &nbsp;2.4.1 Stomach Cancer &nbsp;2.4.2 Liver Cancer &nbsp;2.4.3 Kidney Ccancer &nbsp;2.4.4 Bladder Cancer &nbsp;2.4.5 Cervical Cancer &nbsp;2.4.6 Other &nbsp;2.5 PD-1 and PDL-1 Inhibitors Sales by Application &nbsp;2.5.1 Global PD-1 and PDL-1 Inhibitors Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global PD-1 and PDL-1 Inhibitors Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global PD-1 and PDL-1 Inhibitors Breakdown Data by Company &nbsp;3.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Company (2020-2025) &nbsp;3.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Company (2020-2025) &nbsp;3.2.2 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global PD-1 and PDL-1 Inhibitors Sale Price by Company &nbsp;3.4 Key Manufacturers PD-1 and PDL-1 Inhibitors Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers PD-1 and PDL-1 Inhibitors Product Location Distribution &nbsp;3.4.2 Players PD-1 and PDL-1 Inhibitors Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for PD-1 and PDL-1 Inhibitors by Geographic Region &nbsp;4.1 World Historic PD-1 and PDL-1 Inhibitors Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic PD-1 and PDL-1 Inhibitors Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global PD-1 and PDL-1 Inhibitors Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas PD-1 and PDL-1 Inhibitors Sales Growth &nbsp;4.4 APAC PD-1 and PDL-1 Inhibitors Sales Growth &nbsp;4.5 Europe PD-1 and PDL-1 Inhibitors Sales Growth &nbsp;4.6 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Growth 5 Americas &nbsp;5.1 Americas PD-1 and PDL-1 Inhibitors Sales by Country &nbsp;5.1.1 Americas PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) &nbsp;5.1.2 Americas PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025) &nbsp;5.2 Americas PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025) &nbsp;5.3 Americas PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC PD-1 and PDL-1 Inhibitors Sales by Region &nbsp;6.1.1 APAC PD-1 and PDL-1 Inhibitors Sales by Region (2020-2025) &nbsp;6.1.2 APAC PD-1 and PDL-1 Inhibitors Revenue by Region (2020-2025) &nbsp;6.2 APAC PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025) &nbsp;6.3 APAC PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe PD-1 and PDL-1 Inhibitors by Country &nbsp;7.1.1 Europe PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) &nbsp;7.1.2 Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025) &nbsp;7.2 Europe PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025) &nbsp;7.3 Europe PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa PD-1 and PDL-1 Inhibitors by Country &nbsp;8.1.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of PD-1 and PDL-1 Inhibitors &nbsp;10.3 Manufacturing Process Analysis of PD-1 and PDL-1 Inhibitors &nbsp;10.4 Industry Chain Structure of PD-1 and PDL-1 Inhibitors 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 PD-1 and PDL-1 Inhibitors Distributors &nbsp;11.3 PD-1 and PDL-1 Inhibitors Customer 12 World Forecast Review for PD-1 and PDL-1 Inhibitors by Geographic Region &nbsp;12.1 Global PD-1 and PDL-1 Inhibitors Market Size Forecast by Region &nbsp;12.1.1 Global PD-1 and PDL-1 Inhibitors Forecast by Region (2026-2031) &nbsp;12.1.2 Global PD-1 and PDL-1 Inhibitors Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global PD-1 and PDL-1 Inhibitors Forecast by Type (2026-2031) &nbsp;12.7 Global PD-1 and PDL-1 Inhibitors Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 GlaxoSmithKline plc &nbsp;13.1.1 GlaxoSmithKline plc Company Information &nbsp;13.1.2 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 GlaxoSmithKline plc Main Business Overview &nbsp;13.1.5 GlaxoSmithKline plc Latest Developments &nbsp;13.2 Bristol-Myers Squibb Company &nbsp;13.2.1 Bristol-Myers Squibb Company Company Information &nbsp;13.2.2 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Bristol-Myers Squibb Company Main Business Overview &nbsp;13.2.5 Bristol-Myers Squibb Company Latest Developments &nbsp;13.3 Arcus Biosciences, Inc. &nbsp;13.3.1 Arcus Biosciences, Inc. Company Information &nbsp;13.3.2 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Arcus Biosciences, Inc. Main Business Overview &nbsp;13.3.5 Arcus Biosciences, Inc. Latest Developments &nbsp;13.4 Agenus Inc &nbsp;13.4.1 Agenus Inc Company Information &nbsp;13.4.2 Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Agenus Inc Main Business Overview &nbsp;13.4.5 Agenus Inc Latest Developments &nbsp;13.5 F. Hoffmann-La Roche Ltd &nbsp;13.5.1 F. Hoffmann-La Roche Ltd Company Information &nbsp;13.5.2 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 F. Hoffmann-La Roche Ltd Main Business Overview &nbsp;13.5.5 F. Hoffmann-La Roche Ltd Latest Developments &nbsp;13.6 Astra Zeneca PLC &nbsp;13.6.1 Astra Zeneca PLC Company Information &nbsp;13.6.2 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Astra Zeneca PLC Main Business Overview &nbsp;13.6.5 Astra Zeneca PLC Latest Developments &nbsp;13.7 Beigene Ltd &nbsp;13.7.1 Beigene Ltd Company Information &nbsp;13.7.2 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Beigene Ltd Main Business Overview &nbsp;13.7.5 Beigene Ltd Latest Developments &nbsp;13.8 Incyte Corporation &nbsp;13.8.1 Incyte Corporation Company Information &nbsp;13.8.2 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Incyte Corporation Main Business Overview &nbsp;13.8.5 Incyte Corporation Latest Developments &nbsp;13.9 Biocad &nbsp;13.9.1 Biocad Company Information &nbsp;13.9.2 Biocad PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Biocad Main Business Overview &nbsp;13.9.5 Biocad Latest Developments &nbsp;13.10 CStone Pharmaceuticals &nbsp;13.10.1 CStone Pharmaceuticals Company Information &nbsp;13.10.2 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 CStone Pharmaceuticals Main Business Overview &nbsp;13.10.5 CStone Pharmaceuticals Latest Developments &nbsp;13.11 Ono Pharmaceutical &nbsp;13.11.1 Ono Pharmaceutical Company Information &nbsp;13.11.2 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Ono Pharmaceutical Main Business Overview &nbsp;13.11.5 Ono Pharmaceutical Latest Developments &nbsp;13.12 Merck &nbsp;13.12.1 Merck Company Information &nbsp;13.12.2 Merck PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Merck Main Business Overview &nbsp;13.12.5 Merck Latest Developments &nbsp;13.13 Shanghai Junshi Bioscience Co. Ltd &nbsp;13.13.1 Shanghai Junshi Bioscience Co. Ltd Company Information &nbsp;13.13.2 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Shanghai Junshi Bioscience Co. Ltd Main Business Overview &nbsp;13.13.5 Shanghai Junshi Bioscience Co. Ltd Latest Developments &nbsp;13.14 Shanghai Henlius Biotech, Inc. &nbsp;13.14.1 Shanghai Henlius Biotech, Inc. Company Information &nbsp;13.14.2 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Shanghai Henlius Biotech, Inc. Main Business Overview &nbsp;13.14.5 Shanghai Henlius Biotech, Inc. Latest Developments &nbsp;13.15 Jiangsu HengRui Medicine Co., Ltd. &nbsp;13.15.1 Jiangsu HengRui Medicine Co., Ltd. Company Information &nbsp;13.15.2 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolios and Specifications &nbsp;13.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Jiangsu HengRui Medicine Co., Ltd. Main Business Overview &nbsp;13.15.5 Jiangsu HengRui Medicine Co., Ltd. Latest Developments 14 Research Findings and Conclusion

Report	Global PD-1 and PDL-1 Inhibitors Market Growth 2025-2031
Selected License	Multi ID: LPI10585

Buyer Information

Order Summary